Stock Events

Stock Events

Vaxcyte 

€50.5
0
+€0.5+1% Tuesday 12:47

Statistics

Day High
50.5
Day Low
49.6
52W High
53
52W Low
25.2
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11MayExpected
Q4 2025
Next
-1.54
-1.46
-1.38
-1.3
Expected EPS
-1.48584671629
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5VA.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap149.77B
Pfizer, through its acquisition of Wyeth, is a direct competitor in the pneumococcal vaccine market, competing with Vaxcyte's pneumococcal vaccine candidates.
Merck
MRK
Mkt Cap277.02B
Merck & Co. produces Pneumovax 23, a pneumococcal vaccine that competes with Vaxcyte's vaccine candidates targeting similar diseases.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline competes in the pneumococcal vaccine space with its Synflorix and other pneumococcal vaccine developments, making it a competitor to Vaxcyte.
Sanofi
SNY
Mkt Cap110.4B
Sanofi, through its vaccines division Sanofi Pasteur, is involved in developing vaccines that could compete with Vaxcyte's pneumococcal vaccine candidates.
Novavax
NVAX
Mkt Cap1.32B
Novavax is involved in the development of vaccines for infectious diseases, which could put it in competition with Vaxcyte, especially if it enters the pneumococcal disease space.
BioNTech
BNTX
Mkt Cap24.67B
BioNTech, known for its mRNA technology, could potentially develop vaccines that compete with Vaxcyte's pneumococcal vaccine candidates.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its Janssen Pharmaceuticals division, works on vaccines that could compete with Vaxcyte's offerings in the infectious disease arena.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca has a broad portfolio of vaccines and could become a competitor if it decides to expand into pneumococcal or similar vaccines.

About

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Show more...
CEO
Mr. Grant E. Pickering M.B.A.
Employees
507
Country
United States
ISIN
US92243G1085

Listings

MI
IT
1PCVX.MI
STU
DE
5VA.STU
F
DE
5VA.F
XNAS
US
PCVX

0 Comments

Share your thoughts

FAQ

What is Vaxcyte stock price today?▼
The current price of 5VA.STU is €50.5 EUR — it has increased by +1% in the past 24 hours. Watch Vaxcyte stock price performance more closely on the chart.
What is Vaxcyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vaxcyte stocks are traded under the ticker 5VA.STU.
Is Vaxcyte stock price growing?▼
5VA.STU stock has risen by +3.91% compared to the previous week, the month change is a +0% rise, over the last year Vaxcyte has showed a +72.95% increase.
When is the next Vaxcyte earnings date?▼
Vaxcyte is going to release the next earnings report on May 11, 2026.
What were Vaxcyte earnings last quarter?▼
5VA.STU earnings for the last quarter are -1.54 EUR per share, whereas the estimation was -1.3 EUR resulting in a -18.32% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Vaxcyte have?▼
As of May 06, 2026, the company has 507 employees.
In which sector is Vaxcyte located?▼
Vaxcyte operates in the Health & Wellness sector.
When did Vaxcyte complete a stock split?▼
Vaxcyte has not had any recent stock splits.
Where is Vaxcyte headquartered?▼
Vaxcyte is headquartered in San Carlos, United States.